Cargando…
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
BACKGROUND: Advanced biliary tract cancers (BTCs) have a poor prognosis and limited treatment options. This exploratory phase II study aimed to evaluate the activity of the mTOR inhibitor everolimus in advanced BTC and explore prognostic biomarkers. METHODS: Patients with advanced BTCs, who had not...
Autores principales: | Lau, David K., Tay, Rebecca Y., Yeung, Yvonne H., Chionh, Fiona, Mooi, Jennifer, Murone, Carmel, Skrinos, Effie, Price, Timothy J., Mariadason, John M., Tebbutt, Niall C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931084/ https://www.ncbi.nlm.nih.gov/pubmed/29527009 http://dx.doi.org/10.1038/s41416-018-0021-1 |
Ejemplares similares
-
K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines
por: Yeung, Yvonne, et al.
Publicado: (2017) -
Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010) -
RADIS: analysis of RAD-seq data for interspecific phylogeny
por: Cruaud, Astrid, et al.
Publicado: (2016) -
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2009) -
Diccionario ch'ol-español, español-ch'ol
por: Aulie, H. Wilbur
Publicado: (1978)